BCL2 and diffuse large B-cell lymphoma: Studies on the U-2946 cell line in DLBCL revealed that its unique profile (MCL1 overexpression and lack of BCL-2 expression) results in resistance to BCL-2 inhibitors such as ABT-263, highlighting the need for therapy personalization based on the molecular profile of the tumor [144].